Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates
    • 01/07/2020
    • News

    Suspension of the notice period during temporary unemployment due to Covid-19 force majeure

    On 22 June 2020, the law aiming to suspend notice periods notified by the employer before or during temporary unemployment due to Covid-19 force majeure (Wet tot opschorting van de opzeggingstermijn voor ontslagen gegeven voor of tijdens de periode van tijdelijke schorsing van de uitvoering van de arbeidsovereenkomst omwille van overmacht ingevolge de COVID-19-crisis / Loi visant à suspendre les délais de préavis des congés donnés avant ou durant la période de suspension temporaire de l’exécution du contrat de travail pour cause de force majeure en raison de la crise du COVID-19) was published in the Belgian Official Journal (the Law).

    Read more
    • 26/06/2020
    • News

    Novartis Settles Bribery Charges under Foreign Corrupt Practices Act in Relation to Medicine-Related Conduct in Greece

    Novartis AG, its subsidiary Novartis Hellas S.A.C.I., and its former subsidiary Alcon Pte Ltd (together Novartis) have agreed to pay total fines in excess of US $ 345 million to settle cases started by the US Department of Justice (the DOJ) and the US Securities and Exchange Commission (the SEC) under the US Foreign Corrupt Practices Act (FCPA) (see, attached press releases of 25 June 2020). A significant part of the practices alleged to be in violation of the FCPA took place in Greece. Novartis was under investigation because it had made illicit payments to employees of state-owned or state-controlled health institutions in Greece and had also mischaracterised and falsely recorded these payments in its company books and accounts. For the US agencies, these payments amounted to bribery and their false characterisation as an attempt to cover up a crime. The case serves as a reminder that conduct in Europe engaged in by a European firm and possibly in violation of European pharmaceutical and anti-bribery rules may also give rise to extensive exposure under US anti-corruption laws. Novartis admitted that, between 2012 and 2015, it bribed healthcare professionals in Greece in an attempt to increase the sale of Novartis-branded pharmaceutical products. Specifically, Novartis allowed healthcare professionals to travel overseas to medical congresses, including events held in the United States, in exchange for an assurance that these healthcare professionals would augment the number of prescriptions for Lucentis, a prescription-only ophthalmological medicine. Novartis also admitted that, between 2009 and 2010, it made improper payments to healthcare professionals in connection with an epidemiological study that was intended to increase sales of Novartis-branded prescription medicines. Novartis staff recognised that many participating healthcare professionals understood that they were being paid in exchange for writing prescriptions of Novartis products and not for supplying data as part of a clinical study.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]


  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Commission Reviews First Two Years of GDPR: A Success Story with Room for Improvement

    On 24 June 2020, the European Commission has published its first report on the General Data Protection Regulation (the GDPR) which has applied in the EU since May 2018. Overall, the Commission considers the GDPR to be a success story, but, at the same time, it identifies certain areas where there is room for improvement and the challenges that lie ahead. In particular, the Commission notes that the efficient and coordinated enforcement of the GDPR among all Member States is of paramount importance. Moreover, the application of the GDPR to new technologies, such as artificial intelligence and blockchain, requires continuous monitoring. According to the Commission, the Covid-19 crisis has proved that the use of new technologies and data protection go hand in hand. Please click below for a note summarising the Commission’s report.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.